Condition

Brain Metastases, Adult

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 19 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials19

Recruiting8

Common interventions25

Lead sponsors shown15

Clinical trials

19 shown

Tarlatamab for SCLC Brain MetastasesNCT07402343 · 2026-08-01

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin ReductionNCT07132190 · 2025-12-30

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain MetastasesNCT07130786 · 2025-12-23

Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic TrialNCT06974370 · 2025-06-05

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain MetastasesNCT06401824 · 2025-04-24

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)NCT05689619 · 2023-09-01

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the BrainNCT05419076 · 2022-06-10

BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.NCT06611306 · 2025-01-06

NOT_YET_RECRUITING

JDQ443 for KRAS G12C NSCLC Brain MetastasesNCT05999357 · 2024-04-15

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving ImmunotherapyNCT05703269 · 2023-07-11

ACTIVE_NOT_RECRUITING

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesNCT04711824 · 2022-03-09

ACTIVE_NOT_RECRUITING

Survivorship Study of Cancer Patients Who Received Cranial Radiation TherapyNCT04567251 · 2021-12-28

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesNCT05012254 · 2021-11-18

ACTIVE_NOT_RECRUITING

Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain OligometastasisNCT05144867 · 2021-08-31

Neoadjuvant Immunotherapy in Brain MetastasesNCT04434560 · 2020-11-04

Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic RadiosurgeryNCT04785521 · 2020-07-01

ACTIVE_NOT_RECRUITING

LITT and Pembrolizumab in Recurrent Brain MetastasisNCT04187872 · 2020-01-10

Combining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesNCT02978404 · 2017-06-02

Common interventions

Leading sponsors

Maastricht University Medical Center 3 Ayal A. Aizer, MD 2 A.O.U. Città della Salute e della Scienza 1 Centre hospitalier de l'Université de Montréal (CHUM) 1 Colette Shen 1 Duke University 1 Fundación GECP 1 Imperial College London 1 IRCCS San Raffaele 1 Memorial Sloan Kettering Cancer Center 1 Neonc Technologies, Inc. 1 Post Graduate Institute of Medical Education and Research, Chandigarh 1 Sarah Sammons, MD 1 University of Florida 1 University of Vermont Medical Center 1

Trial status mix

RECRUITING8

ACTIVE_NOT_RECRUITING4

TERMINATED3

COMPLETED1

NOT_YET_RECRUITING1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE212

NA3

PHASE13

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.